Cbdmedic Active Sport Pain Relief
Camphor And Menthol
Abacus Health Products, Inc.
Human Otc Drug
NDC 73096-741Cbdmedic Active Sport Pain Relief also known as Camphor And Menthol is a human otc drug labeled by 'Abacus Health Products, Inc.'. National Drug Code (NDC) number for Cbdmedic Active Sport Pain Relief is 73096-741. This drug is available in dosage form of Stick. The names of the active, medicinal ingredients in Cbdmedic Active Sport Pain Relief drug includes Camphor (natural) - 100 mg/g Menthol - 150 mg/g . The currest status of Cbdmedic Active Sport Pain Relief drug is Active.
Drug Information:
| Drug NDC: | 73096-741 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Cbdmedic Active Sport Pain Relief |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Camphor And Menthol |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Abacus Health Products, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Stick |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAMPHOR (NATURAL) - 100 mg/g
MENTHOL - 150 mg/g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Sep, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 22 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | ABACUS HEALTH PRODUCTS, INC.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | N20HL7Q941
L7T10EIP3A
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 73096-741-30 | 1 CYLINDER in 1 CARTON (73096-741-30) / 30 g in 1 CYLINDER | 01 Sep, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Product Elements:
Cbdmedic active sport pain relief camphor and menthol white wax clove oil cottonseed oil frankincense oil hemp lonicera confusa whole jojoba oil myrrh oil shea butter sorbic acid camphor (natural) camphor (natural) menthol menthol
Indications and Usage:
Uses temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains
Warnings:
Warnings for external use only do not use on ⢠wounds or damaged skin when using this product ⢠avoid contact with eyes or mucous membranes ⢠do not bandage tightly or use with a heating pad stop use and ask a doctor if ⢠condition worsens ⢠symptoms persist for more than 7 days ⢠symptoms clear up and occur again within a few days ⢠excessive skin irritation develops if pregnant or breast-feeding ask a health professional before use keep out of reach of children if swallowed, get medical help or contact a poison control center immediately
Dosage and Administration:
Directions adults and children 12 years of age and older: ⢠apply to affected area not more than 3 to 4 times daily ⢠wash hands with soap and water after use (unless applying to hands) children under 12 years of age: ask a doctor
Package Label Principal Display Panel:
Principal display panel label